Georgia Tech Research Corporation

Emory University

Other

Queen's University at Kingston

Children's Healthcare of Atlanta, Inc.

Kingston Health Sciences Centre

Columbia University

Eric Gaucher

Christopher B Doering

Philip M Zakas

H Trent Spencer

Harold Trent Spencer

Caelan Radford

David Lillicrap

Julio M Fernandez

Raul Perez-Jimenez

Pallav Kosuri

A recombinant von Willebrand Factor (VWF) protein comprising one or more mutations and uses thereof are described. A recombinant protein complex comprising a von Willebrand factor sequence and one artificial Factor VIII sequence is described. A recombinant protein complex comprising a Factor VIII sequence and one artificial von Willebrand sequence is described. A recombinant protein complex is described that includes one artificial von Willebrand factor sequence and one artificial Factor VIII sequence. Also described are nucleic acid sequences and a vector encoding a VWF sequence and a pharmaceutical composition for inducing blood clotting that includes a VWF protein.

Von Willebrand factor proteins for treating bleeding disorders

This disclosure relates to recombinant or chimeric FVIII proteins, variants, and vectors encoding the proteins containing one or more ancestral mutations. In certain embodiments, one or more protein domains comprise amino acid sequences that are derived from ancestrally reconstructed amino acid sequences. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising the proteins or vectors and related methods of inducing blood clotting.

Factor VIII proteins having ancestral sequences, expression vectors, and uses related thereto

Disclosed herein are novel variants of clotting factors VII, VIII, and IX and their use, for example, in methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B.

Nucleic acids encoding clotting factor variants and their use

This patent applications concerns compositions of matter that are DNA polymerases, where those polymerases have had one or more of their amino acids replaced at sites chosen by an analysis of patterns of conservation and replacement within homologous protein sequences. Disclosed here are sites within Family A DNA polymerases where amino acid replacement creates polymerases having utility, in an example where DNA nucleotides are incorporated having modified or unnatural nucleobases, and/or nucleotides whose sugar is unnatural or derivatized, including 3'-O-amino-2&#x2032;-deoxyribonucleoside triphosphates. The claimed compositions include polymerases that hold amino acid replacements at claimed sites in Taq polymerase, and are prepared by site-directed mutagenesis that modifies a gene encoding a parent Taq gene (natural or already mutated) to change the codon encoding the amino acid at the claimed site, giving a variant gene that encodes a Taq polymerase protein that has a different amino acid at the claimed site.

Taq polymerase sequences useful for incorporating analogs of nucleoside triphosphates

The present invention provides uricases and methods of their production and use in reducing the amount of uric acid in a subject. The present invention further provides methods employing a uricase of this invention in the treatment and/or prevention of hyperuricemia, gout, tumor lysis syndrome and/or hypertension in a subject.

Variants of ancestral uricases and uses thereof

Growing community of inventors

Atlanta, GA, United States of America

Eric Gaucher